TG01 + QS-21 +/- Balstilimab for Pancreatic Cancer
(TESLA Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial is testing a new drug, TG01, to help the immune system fight leftover cancer cells after pancreatic surgery. It also tests if combining TG01 with another drug, Balstilimab, works better. The study focuses on patients who have had pancreatic cancer surgery.
Will I have to stop taking my current medications?
The trial does not specify if you need to stop taking your current medications, but you cannot use other cancer treatments or drugs that affect the immune system unless they are at low doses. It's best to discuss your specific medications with the trial team.
What makes the TG01 + QS-21 +/- Balstilimab treatment unique for pancreatic cancer?
The TG01 + QS-21 +/- Balstilimab treatment is unique because it combines a vaccine approach with an immune system booster (QS-21) and potentially an immune checkpoint inhibitor (Balstilimab), aiming to enhance the body's immune response against pancreatic cancer, which is known for its challenging immune environment.12345
What data supports the effectiveness of the treatment TG01 + QS-21 +/- Balstilimab for pancreatic cancer?
Research on similar treatments, like the GVAX vaccine combined with other drugs, shows that these combinations can increase immune cell activity in pancreatic cancer, which might help fight the cancer. Although not directly related to TG01 + QS-21 +/- Balstilimab, these findings suggest that combining vaccines with immune-boosting drugs could be promising for pancreatic cancer.12567
Who Is on the Research Team?
Anup Kasi, MD
Principal Investigator
The University of Kansas Cancer Center
Are You a Good Fit for This Trial?
Adults over 18 with resected stage I/II/III Pancreatic Cancer, positive for MRD, and specific RAS mutations. They must have completed prior cancer treatment at least 14 days before and recovered from its effects. Women of childbearing potential need a negative pregnancy test and agree to contraception.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Priming/Booster Treatment
Participants receive TG01 vaccine mixed with QS-21 every two weeks for 12 weeks
Maintenance Treatment
Participants receive TG01 vaccine mixed with QS-21 every 8 weeks for up to 51 weeks
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Balstilimab
- TG01 Vaccine
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Kansas Medical Center
Lead Sponsor
Targovax ASA
Industry Sponsor